Evidence map›Paper›PMID 41861098›Full record

ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Bilirubin as a Modulator of WNK1 Protein Signaling: Implications for Neuroinflammatory Diseases.

Sri Jayanti, Libor Vítek, Silvia Gazzin, Claudio Tiribelli

Abstract readReview
In one paragraph

Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sri JayantiEijkman Research Center for Molecular Biology, National Research and Innovation Agency of Indonesia, Jakarta, Indonesia.ORCID https://orcid.org/0000-0003-4554-504X
Libor VítekGeneral University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic.ORCID https://orcid.org/0000-0002-5318-0151
Silvia GazzinLiver-Brain Unit "Rita Moretti,", Fondazione Italiana Fegato-ONLUS, Trieste, Italy.ORCID https://orcid.org/0000-0001-9403-3564
Claudio TiribelliLiver-Brain Unit "Rita Moretti,", Fondazione Italiana Fegato-ONLUS, Trieste, Italy.ORCID https://orcid.org/0000-0001-6596-7595

Funding

Czech Ministry of Health MH CZ-DRO-VFN64165Czech Ministry of Health and the Inter-Action project LUAUS26259
6 · The paper itself

Abstract

Previously regarded merely as a potentially harmful waste product of heme catabolism, bilirubin has now emerged as a pleiotropic molecule with potent antioxidant, anti-inflammatory, and hormone-like properties. Recent findings have revealed protective effects against cardiovascular, metabolic, autoimmune, and neoplastic diseases, as well as neurological disorders. The growing understanding of neuroinflammatory processes has opened new avenues for exploring the role of bilirubin in neuroprotection. Despite the increasing number of studies investigating the protective effects of bilirubin in neurological diseases, the molecular mechanisms underlying its anti-inflammatory actions in the brain remain insufficiently understood. In this perspective article, With-No-Lysine (K) kinase 1 (WNK1) is discussed as a newly identified molecular target of bilirubin, highlighting its potential implications for neuroinflammatory diseases. The bilirubin-WNK1 axis may represent a previously unrecognized protective mechanism that could be leveraged to mitigate inflammation-driven neurodegeneration. This interaction can open new therapeutic opportunities for neurodegenerative disorders such as multiple sclerosis (MS), Alzheimer's disease, and Parkinson's disease.

Indexed as

BilirubinNeurodegenerative DiseasesNeuroinflammatory DiseasesSignal TransductionWNK Lysine-Deficient Protein Kinase 1AnimalsHumansBilirubinWNK1 protein, humanWNK Lysine-Deficient Protein Kinase 1bilirubinneurodegenerative diseasesneuroinflammationneuroprotectionWNK1

Identifiers

PMID41861098
PMCPMC13170186

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.